alexa Dysostosis Multiplex (Gm-1 Gangliosidosis: Type II) | Open Access Journals
Cardiovascular Therapy: Open Access
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Dysostosis Multiplex (Gm-1 Gangliosidosis: Type II)

Madhu KJ1*, Vijyalakshmi IB2, Chitra Narsimhan2 and CN Manjunath1

1Department of Cardiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, India

2Department of Pediatrics Cardiology, Sri Jayadeva Institute of cardiovascular Sciences and Research, India

*Corresponding Author:
Madhu KJ
Department of Cardiology
Sri Jayadeva Institute of Cardiovascular Sciences and Research, India
Tel: +9902783016
E-mail: [email protected]

Received date: December 24, 2015; Accepted date: January 05, 2016; Published date: January 11, 2016

Citation: Madhu KJ, Vijyalakshmi IB, Narsimhan C, Manjunath CN (2016) Dysostosis Multiplex (Gm-1 Gangliosidosis: Type II).  Cardiovasc Ther 1:101.

Copyright: © 2016 Madhu KJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Cardiovascular Therapy: Open Access

Abstract

GM1 gangliosidosis is an autosomal recessive lysosomal storage disorder characterized by the generalized accumulation of GM1 ganglioside, oligosaccharides, and the mucopolysaccharide keratan sulfate (and their derivatives). Deficiency of the lysosomal hydrolase, acid β -galactosidase, causes GM1 gangliosidosis. GM1 gangliosidosis is a rare disorder, and the estimated incidence is 1:100,000- 200,000 live births. GM1 gangliosidosis is found in all races, although specific alleles can be identified in certain ethnic groups. A high frequency of GM1 gangliosidosis has been reported from Southern Brazil, and a large number of Japanese patients with the adult form have been reported. All 3 types of GM1 gangliosidosis are inherited as autosomal recessive traits and have equal sex distributions.

Keywords

Mucopolysachroid; Keratan sulphate; Dermal melanocytosis;Autosomal recessive

Introduction

GM1 gangliosidosis is an autosomal recessive lysosomal storage disorder characterized by the generalized accumulation of GM1 ganglioside, oligosaccharides, and the mucopolysaccharidekeratan sulfate (and their derivatives). Deficiency of the lysosomal hydrolase, acid β-galactosidase, causes GM1 gangliosidosis [1]. GM1 gangliosidosis is a rare disorder, and the estimated incidence is 1:100,000-200,000 live births [2]. GM1 gangliosidosis is found in all races, although specific alleles can be identified in certain ethnic groups. A high frequency of GM1 gangliosidosis has been reported from Southern Brazil, and a large number of Japanese patients with the adult form have been reported [3]. All 3 types of GM1 gangliosidosis are inherited as autosomal recessive traits and have equal sex distributions.

Case Report

5 years old boy with normal birth history born to a nonconsanginous parents, presented with mild developmental delay, gait difficulties and stiffness of limbs since 4 year of age. Initially parents noticed child had tiptoe walking, later he had stiffness of both upper and lower limbs which is gradually progressive. Child is still able to walk but unable to run. There is history of febrile seizures at 1.5 year of age. Younger sibling also having similar complaints

On examination

Boy is alert, cooperative GPE revealed, Coarse facial features, proptosis, prominent forehead, tented upper lip, hepatosplenomegaly, melanotic patches over back, elbow, finger & hamstrings contracture, protrubrent abdomen with umbilical hernia, brisk reflexes, power 5/5 and spastic gait.

Investigations

CBC showed normocytic hypochromic with mild relative monocytosis, LFT’ & RFT’s were normal, Urine test positive for MPS, Serum Hexosaminidase. A enzyme levels raised above normal limits, Aryl sulfatase negative, Beta galactosidase enzyme levels were reduced.

Cardiac evaluation

Mild MR, MVP, dilated LV, pericardial thickening, depositions over heart valves, chordae, endocardium and pericardium

X-ray

Thick calavaria, J shaped sella, Beaked vertebra

MRI brain

Prominent elongated perivascular spaces were noted in bilateral posterior

and lobar white matter, as well as corpus callosum and centrum semiovale. T2 FLAIR white matter signal changes are also noted in these regions (sparing the corpus callosum [4]). Sella appears J shaped (Figures 1-4)

cardiovascular-therapy-hypertelorism

Figure 1: Showing prominent forehead, hypertelorism, proptosis, flat nasal bridge, tented upperlip, umbilical hernis, elbow contracture.

cardiovascular-therapy-hamstrings

Figure 2: Showing large and low set ear, beaded appearance of ribs, lumbar larosis, hamstrings contracture, finger contracture, protrubrent abdomen with hepatosplenomegaly.

cardiovascular-therapy-characterized

Figure 3: Showing Dermal Melanocytosis, characterized by extensive blue cutaneous pigmentation with dorsal and ventral distribution with indistinct border.

cardiovascular-therapy-echocardiography

Figure 4: Echocardiography image showing deposits over mitral valve, endocardium, myocardium and pericardium.

Discussion

Acid β -galactosidase is a lysosomal hydrolase that catalyzes the removal of the terminal β-linked galactose from glycoconjugates (eg, GM1 ganglioside), generating GM2 ganglioside. It also functions to degrade other β-galactose–containing glycoconjugates, such as keratan sulfate.

Enzyme activity is markedly reduced in patients with GM1 gangliosidosis. Deficiency of acid β-galactosidase results in the accumulation of glycoconjugates in body tissues and their excretion in urine. GM1 ganglioside and its derivative asialo-GM1ganglioside (GA1), glycoprotein-derived oligosaccharides, and keratan sulfate are found at elevated intracellular concentrations[1,5-8]. The gene has been isolated and is located on chromosome band 3p21.33. Various types of mutations have been identified in the acid β-galactosidase gene, including missense/nonsense, duplication/insertion, and splice site abnormalities [9].

Three clinical subtypes

There are of GM1 gangliosidosis are recognized.

The infantile form (Type 1): Typically presents between birth and age 6 months with progressive organomegaly, dysostosis multiplex, facial coarsening, and rapid neurologic deterioration withi the first year of life. Death usually occurs during the second year of life because of infection (usually due to pneumonia that results from recurrent aspiration) and cardiopulmonary failure [10]

The juvenile form (Type 2): Typically presents at age 1-2 years with progressive psychomotor retardation. Little visceromegaly and milder skeletal disease are present compared to the infantile form. Death usually occurs before the second decade of life.

The adult form (Type 3): Typically presents during childhood or adolescence as a slowly progressive dementia with prominent parkinsonian features and extrapyramidal disease, particularly dystonia. Marked phenotypic variability may occur. Age at death may widely vary.

Other clinical features of GM1 Ganglosiadosis are

Neurological features: Developmental delay [11], arrest, and regression, Generalized hypotonia initially, developing into spasticity, Exaggerated startle response, Hyperreflexia, Seizures, Extrapyramidal disease, Generalized dystonia (adult subtype) [12], Ataxia, Dementia, Speech and swallowing disturbance [13].

Opthalmaologic features: Macular cherry-red spots, Optic atrophy, Corneal clouding

Dysmorphic features: Frontal bossing, Depressed nasal bridge and broad nasal tip, Large low-set ears, Long philtrum, Gingival hypertrophy and macroglossia [1], Coarse skin, Hirsutism, Cardiovascular - Dilated and/or hypertrophic cardiomyopathy, valvulopathy.

Per abdomen: Hepatosplenomegaly, Inguinal hernia.

Skeletal abnormalities: Lumbar gibbus deformity and kyphoscoliosis, Dysostosis multiplex, Broad hands and feet, Brachydactyly, Joint contractures, Prominent dermal melanocytosis [14-17].

Diagnosis

Diagnosis of G M1 gangliosidosis can be confirmed by measurement of acid β-galactosidase activity in peripheral blood leukocytes. Patients with the infantile form have almost no enzyme activity, whereas patients with the adult form may have residual activity of 5-10% of reference values.

Urine

Galactose-containing oligosaccharides are excreted in the urine. Their presence may be used as an ancillary diagnostic test, and the concentration of the metabolites is proportional to disease severity.

CBC count

Vacuolation of lymphocytes may be present in patients with GM1 gangliosidosis but is a nonspecific.

Dried blood spots

Diagnosis of GM1 gangliosidosis has been made based on dried blood spots from newborn screening filter paper, even after 15 months in storage [18].

Molecular analysis

Molecular analysis of the β-1 galactosidase gene (GLB1) is clinically available [9].

Prenatal diagnosis

Prenatal diagnosis has been performed successfully by assay of β-galactosidase activity in cultured amniocytes or amniotic chorionic villi [1]. Mutation identification allows prenatal or preimplantation genetic diagnosis [19,20].

Treatment

Currently, no effective medical treatment is available for the underlying disorder in patients with GM1 gangliosidosis. Bone marrow transplantation was successful in an individual with infantile/juvenile GM1 gangliosidosis; however, no long-term benefit was reported [21]. Presymptomatic cord-blood hematopoietic stem-cell transplantation has been advocated by some as a possible treatment because of success in other lysosomal storage disorders [22]. Symptomatic treatment for some neurologic sequelae is available but does not significantly alter the clinical course. Active research in the areas of enzyme replacement and gene therapy for GM1 gangliosidosis is ongoing but has not advanced to human trials [2].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Recommended Conferences

Article Usage

  • Total views: 7864
  • [From(publication date):
    February-2016 - Jun 27, 2017]
  • Breakdown by view type
  • HTML page views : 7822
  • PDF downloads :42
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords